Hartford Investment Management Co. Sells 508 Shares of Boston Scientific Corporation $BSX

Hartford Investment Management Co. lessened its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 0.6% during the second quarter, Holdings Channel.com reports. The firm owned 89,433 shares of the medical equipment provider’s stock after selling 508 shares during the period. Hartford Investment Management Co.’s holdings in Boston Scientific were worth $9,606,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC boosted its holdings in Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after acquiring an additional 226 shares in the last quarter. Ameriflex Group Inc. acquired a new position in shares of Boston Scientific during the fourth quarter worth approximately $31,000. PKO Investment Management Joint Stock Co bought a new position in shares of Boston Scientific in the 4th quarter worth $893,000. MassMutual Private Wealth & Trust FSB grew its position in Boston Scientific by 17.5% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 6,325 shares of the medical equipment provider’s stock valued at $638,000 after purchasing an additional 940 shares during the period. Finally, Neville Rodie & Shaw Inc. bought a new stake in Boston Scientific during the 1st quarter valued at $2,341,000. 89.07% of the stock is owned by institutional investors.

Insider Transactions at Boston Scientific

In related news, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the sale, the director owned 2,081 shares of the company’s stock, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the sale, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 174,214 shares of company stock valued at $18,397,457. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Stock Performance

NYSE BSX opened at $98.03 on Friday. The company has a market capitalization of $145.26 billion, a PE ratio of 58.35, a price-to-earnings-growth ratio of 2.36 and a beta of 0.65. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. Boston Scientific Corporation has a 52-week low of $80.64 and a 52-week high of $109.50. The company has a 50-day simple moving average of $103.90 and a 200 day simple moving average of $102.06.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the prior year, the firm earned $0.62 EPS. The company’s revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have weighed in on BSX shares. Robert W. Baird raised their price objective on shares of Boston Scientific from $117.00 to $123.00 and gave the company an “outperform” rating in a research note on Thursday, July 24th. Oppenheimer raised shares of Boston Scientific from a “market perform” rating to an “outperform” rating and raised their price target for the company from $118.00 to $125.00 in a research report on Monday, September 8th. UBS Group lifted their price target on Boston Scientific from $130.00 to $135.00 and gave the company a “buy” rating in a research note on Thursday, July 24th. Raymond James Financial increased their price objective on Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a research note on Thursday, July 24th. Finally, Leerink Partnrs raised Boston Scientific to a “strong-buy” rating in a research report on Monday, June 16th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, Boston Scientific has a consensus rating of “Buy” and a consensus price target of $118.17.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.